Fiasp (fast-acting insulin aspart) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 7 Diseases   12 Trials   12 Trials   850 News 


123456789»
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Afrezza (recombinant human insulin inhalation) / MannKind, Apidra (insulin glulisine) / Sanofi
    Review, Journal:  Prandial Insulins: A Person-Centered Choice. (Pubmed Central) -  Apr 3, 2024   
    The Technosphere insulin offers an inhaled route for prandial insulin delivery...Ongoing research is focused on refining prandial insulin replacement and exploring newer delivery methods. The article provides a comprehensive overview of various prandial insulin options and their clinical applications in the management of diabetes.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    NOCTURNAL GLUCOSE PROFILE IS RELATED TO PRE?DINNER RAPID INSULIN INJECTION TIMING AND TYPE () -  Mar 6, 2024 - Abstract #ATTD2024ATTD_1079;    
    Mealtime URAI improves 1- and 2-hour postprandial glycemic control compared to RAI without increasing hypoglycemia or weight gain. The timing and type of dinner prandial insulin injection affects the entire nocturnal glucose profile.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Enrollment closed, Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Mar 5, 2024   
    P3,  N=319, Active, not recruiting, 
    The timing and type of dinner prandial insulin injection affects the entire nocturnal glucose profile. Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Sep 2024
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
    Journal:  Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogues in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes. (Pubmed Central) -  Feb 5, 2024   
    P=N/A
    In contrast, there were no significant differences in iAUC-2h, iAUC-4h, and the other measures of postprandial glucose control between insulin aspart and Fiasp during breakfast, lunch, and evening meal (p>0.05). Conclusion The use of Lyumjev with CamAPS FX closed-loop system improved postprandial glucose excursions compared with insulin lispro, while the use of Fiasp did not provide any advantage compared with insulin aspart.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Jan 5, 2024   
    P3,  N=264, Recruiting, 
    Conclusion The use of Lyumjev with CamAPS FX closed-loop system improved postprandial glucose excursions compared with insulin lispro, while the use of Fiasp did not provide any advantage compared with insulin aspart. Trial completion date: Apr 2024 --> Apr 2025
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Evaluation of the MiniMed (clinicaltrials.gov) -  Dec 31, 2023   
    P=N/A,  N=250, Recruiting, 
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) -  Dec 26, 2023   
    P3,  N=139, Completed, 
    Trial completion date: Apr 2024 --> Apr 2025 Recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Review, Journal:  The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus. (Pubmed Central) -  Nov 8, 2023   
    Unfortunately, there are only few available recommendations from authoritative sources for use of URAA in clinical practice. Therefore, this expert consensus report aims to define populations of people with diabetes mellitus for whom URAA may be beneficial and to provide health care professionals with concrete, practical recommendations on how best to use URAA in this context.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Review, Journal:  New Insulins for Type 1 Diabetes treatment (Pubmed Central) -  Nov 4, 2023   
    New technologies under development include biosimilar insulins such as the glargine biosimilar, already available in the clinic. New formulations are being developed for the future, as well as novel ways of dispersing them, mimicking the action of pancreatic cells, which will allow a more physiological and personalized management of the disease.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Evaluation of the MiniMed (clinicaltrials.gov) -  Oct 26, 2023   
    P=N/A,  N=250, Recruiting, 
    Faster aspart can be used in women with type 1 or type 2 diabetes during pregnancy and post-delivery with no additional safety issues. Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Feb 2024 --> May 2024
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Real-world evidence, Real-world:  CONNECT 1: A Research Study Looking at How the Use of NovoPen (clinicaltrials.gov) -  Sep 21, 2023   
    P=N/A,  N=227, Enrolling by invitation, 
    Active, not recruiting --> Completed Trial completion date: Mar 2024 --> Sep 2024
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Sep 13, 2023   
    P3,  N=264, Recruiting, 
    Trial completion date: Mar 2024 --> Sep 2024 Trial primary completion date: Aug 2023 --> Dec 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes (clinicaltrials.gov) -  Sep 1, 2023   
    P4,  N=40, Completed, 
    Real-world data confirm that use of FIAsp in insulin pumps in paediatric populations improves glycaemic control long-term. Recruiting --> Completed | Trial completion date: Nov 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  Journal:  Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019. (Pubmed Central) -  Jun 20, 2023   
    Net prices of short-acting insulin increased at an annual rate of 5.6% from 2012 to 2017 but then decreased from 2018 to 2019 after the introduction of insulin aspart (Fiasp) and lispro (Admelog)...In this longitudinal study of US insulin products, results suggest that insulin prices substantially increased from 2012 to 2015, even after accounting for discounts. The introduction of new insulin products was followed by substantial discounting practices that lowered net prices faced by payers.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Evaluation of the MiniMed (clinicaltrials.gov) -  Jun 18, 2023   
    P=N/A,  N=250, Recruiting, 
    The introduction of new insulin products was followed by substantial discounting practices that lowered net prices faced by payers. Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Aug 2023 --> Jan 2024
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Journal, Real-world evidence, Real-world, Metastases:  Real-World User and Clinician Perspective and Experience with MiniMed (Pubmed Central) -  Jun 6, 2023   
    The use of the AHCL system in T1DM resulted in robust glycemic control, minimizing hypoglycemia. Providing training to both users and HCPs can help them use the system effectively.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  May 8, 2023   
    P3,  N=264, Recruiting, 
    Clinical trials registration: NCT04759144. Trial primary completion date: Apr 2023 --> Aug 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) -  Apr 25, 2023   
    P3,  N=160, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    CopenFast Trial (Room 23; [Board No. 176]) -  Apr 10, 2023 - Abstract #ADA2023ADA_984;    
    These real-world data confirm associations between missed basal and bolus insulin doses and impaired TIR, highlighting a need for digital tools such as smart insulin pens to help individuals manage their diabetes. In pregnant women with type 1 or type 2 diabetes, use of faster aspart resulted in comparable fetal growth and HbA1c with less severe hypoglycemia compared to IAsp.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Late Postprandial Hypoglycemia Is Reduced with Ultrarapid Insulin (Poster Halls B-C; [Board No. 817]) -  Apr 10, 2023 - Abstract #ADA2023ADA_501;    
    Given the importance of BG control, hospitals should work to optimize meal insulin delivery and develop strategies to address bedtime food intake. Postprandial glucometrics and LPH (glucose <70mg/dL 2-5 hours after a meal) were evaluated according to insulin injection time and type: rapid (RI) or ultrarapid analog-Fiasp
  • ||||||||||  Symlin (pramlintide) / AstraZeneca
    A Pilot Study Evaluating an Insulin and Pramlintide Fully Closed-Loop Delivery System (Room 29; [Board No. 60]) -  Apr 10, 2023 - Abstract #ADA2023ADA_120;    
    The mean total insulin used throughout the interventions was 38.2 (23.5) units on the control arm, 31.8 (18.4) and 32.5 (17.5) on the faster aspart 1:8 and 1:10 respectively, and 36.6 (26.9) and 32.2 (23.5) on the insulin aspart 1:8 and 1:10 arms respectively. This pilot study suggests that our fully automated dual-hormone delivery system has the potential to alleviate carbohydrate counting without degrading time in the target range; and it will be investigated in a larger subsequent study.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (clinicaltrials.gov) -  Mar 31, 2023   
    P1,  N=40, Recruiting, 
    This pilot study suggests that our fully automated dual-hormone delivery system has the potential to alleviate carbohydrate counting without degrading time in the target range; and it will be investigated in a larger subsequent study. Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Nov 2023
  • ||||||||||  Symlin (pramlintide) / AstraZeneca
    Enrollment closed, Trial completion date, Trial primary completion date:  FCL: A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes (clinicaltrials.gov) -  Mar 14, 2023   
    P=N/A,  N=10, Active, not recruiting, 
    Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Nov 2023 Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Aug 2022 --> May 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    ADVANCED HYBRID CLOSE LOOP SYSTEM DURINGATHLETICS HIGH-PERFORMANCE COMPETITION:A CASE REPORT () -  Feb 23, 2023 - Abstract #ATTD2023ATTD_603;    
    Givenadvances in technology, there is little evidence on high-perfor-mance competition and Advanced Hybrid Close Loop System(AHCL) We present the case of a woman with T1DM, user ofAHCL, during Bolivarian Games 2022.Patient female 25 years old, with 17 years of evo-lution of DM1, in treatment with Faster Aspart and Minimed780G for 1.5 year...The use of MiniMed 780g in addition to dia-betes exercise strategies are effective in achieving metabolictargets during high-performance competition. Further research isneeded to generate recommendations.